| A | B | C | D | E | |
|---|---|---|---|---|---|
1 | Interventions: Codes_and_Descriptions | Average Cost per DALY averted | Incremental Cost per DALY averted | ||
2 | HIV-1 : Peer education for sex workers [EDS] (50% coverage) | 4 | Dominated | ||
3 | HIV-2 : Peer education for sex workers [EDS] (80% coverage) | 4 | Dominated | ||
4 | HIV-3 : Peer education for sex workers [EDS] (95% coverage) | 4 | Dominated | ||
5 | HIV-4 : Combination: EDS + provision of treatment for STI (50% coverage) | 4 | Dominated | ||
6 | HIV-5 : Combination: EDS + provision of treatment for STI (80% coverage) | 4 | Dominated | ||
7 | HIV-6 : Combination: EDS + provision of treatment for STI (95% coverage) | 4 | Dominated | ||
8 | HIV-7 : Mass media [MED] (100%) | 3 | 3 | ||
9 | HIV-8 : School-based education [SDE] (50% coverage) | 530 | Dominated | ||
10 | HIV-9 : School-based education [SDE] (80% coverage) | 444 | Dominated | ||
11 | HIV-10 : School-based education [SDE] (95% coverage) | 376 | Dominated | ||
12 | HIV-11 : Treatment of sexually-transmitted infections [STI] (current coverage) | 19 | Dominated | ||
13 | HIV-12 : Treatment of sexually-transmitted infections [STI] (enhanced coverage) | 21 | Dominated | ||
14 | HIV-13 : Treatment of sexually-transmitted infections [STI] (95 % coverage) | 32 | Dominated | ||
15 | HIV-14 : Voluntary counseling & testing [VCT] at 95% coverage | 82 | Dominated | ||
16 | HIV-15 : Prevention of Mother-to-Child-Transmission (PMTCT) | 34 | Dominated | ||
17 | HIV-16 : Highly Active Anti-Retroviral Therapy (HAART) simple | 556 | Dominated | ||
18 | HIV-17 : HAART (simple) + Directly Observed Treatment Strategy (DOTS) for TB | 596 | Dominated | ||
19 | HIV-18 : HAART Plus (interleukin 2) | 2010 | Dominated | ||
20 | HIV-19 : HAART Plus + DOTS for TB | 1977 | Dominated | ||
21 | HIV-20: Combination: MED + EDS50 | 4 | Dominated | ||
22 | HIV-21: Combination: MED + EDS80 | 4 | Dominated | ||
23 | HIV-22: Combination: MED + EDS95 | 4 | Dominated | ||
24 | HIV-23: Combination: MED + EDS-STI50 | 4 | 4 | ||
25 | HIV-24: Combination: MED + EDS-STI80 | 4 | 4 | ||
26 | HIV-25: Combination: MED + EDS-STI95 | 4 | 4 | ||
27 | HIV-26: Combination: EDS-STI95 + STIcurrent | 5 | Dominated | ||
28 | HIV-27: Combination: EDS-STI95 + STIenhanced | 8 | Dominated | ||
29 | HIV-28: Combination: EDS-STI95 + STI95% | 13 | Dominated | ||
30 | HIV-29: Combination: MED + EDS-STI95 + STIcurrent | 5 | Dominated | ||
31 | HIV-30: Combination: MED + EDS-STI95 + STIenhanced | 8 | Dominated | ||
32 | HIV-31: Combination: MED + EDS-STI95 + STI95% | 12 | Dominated | ||
33 | HIV-32: Combination: MED + EDS-STI95 + STI95% + PMTCT | 16 | Dominated | ||
34 | HIV-33: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE50 | 18 | Dominated | ||
35 | HIV-34: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE80 | 19 | Dominated | ||
36 | HIV-35: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 | 19 | Dominated | ||
37 | HIV-36: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + VCT | 30 | Dominated | ||
38 | HIV-37: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + VCT + HAARTSimpNoDOTS | 66 | 631 | ||
39 | HIV-38: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + VCT + HAARTSimpDOTS | 70 | 1144 | ||
40 | HIV-39: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + VCT + HAARTPlusNoDOTS | 205 | Dominated | ||
41 | HIV-40: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + VCT + HAARTPlusDOTS | 217 | 5175 | ||
42 | HIV-41: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + HAARTSimpNoDOTS | 58 | Dominated | ||
43 | HIV-42: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + HAARTSimpDOTS | 62 | Dominated | ||
44 | HIV-43: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + HAARTPlusNoDOTS | 204 | Dominated | ||
45 | HIV-44: Combination: MED + EDS-STI95 + STI95% + PMTCT + SBE95 + HAARTPlusDOTS | 218 | Dominated | ||
46 | HIV-45: Combination: MED + EDS-STI95 +STI95% + PMTCT + HAARTSimpNoDOTS | 55 | Dominated | ||
47 | HIV-46: Combination: MED + EDS-STI95 + STI95% + PMTCT + HAARTSimpDOTS | 60 | Dominated | ||
48 | HIV-47: Combination: MED + EDS-STI95 + STI95% + PMTCT + HAARTPlusNoDOTS | 203 | Dominated | ||
49 | HIV-48: Combination: MED + EDS-STI95 + STI95% + PMTCT + HAARTPlusDOTS | 216 | Dominated | ||
50 | HIV-49: Combination: MED + EDS-STI95 + STI95% + PMTCT + VCT + HAARTSimpNoDOTS | 64 | 547 | ||
51 | HIV-50: Combination: MED + EDS-STI95 + STI95% + PMTCT + VCT + HAARTSimpDOTS | 68 | Dominated | ||
52 | HIV-51: Combination: MED + EDS-STI95 + STI95% + PMTCT + VCT + HAARTPlusNoDOTS | 203 | Dominated | ||
53 | HIV-52: Combination: MED + EDS-STI95 + STI95% + PMTCT + VCT + HAARTPlusDOTS | 216 | Dominated | ||
54 | HIV-53: Combination: MED + EDS-STI95 + STI95% HAARTSimpNoDOTS | 56 | Dominated | ||
55 | HIV-54: Combination: MED + EDS-STI95 + STI95% HAARTSimpDOTS | 61 | Dominated | ||
56 | HIV-55: Combination: MED + EDS-STI95 + STI95% HAARTPlusNoDOTS | 221 | Dominated | ||
57 | HIV-56: Combination: MED + EDS-STI95 + STI95% HAARTPlusDOTS | 235 | Dominated | ||
58 | HIV-57: Combination: MED + EDS-STI95 + PMTCT | 9 | 46 | ||
59 | HIV-58: Combination: MED + EDS-STI95 + PMTCT + STIcurrent | 10 | 68 | ||
60 | HIV-59: Combination: MED + EDS-STI95 + PMTCT + STIenhanced | 12 | 80 | ||
61 | HIV-60: Combination: MED + STIenhanced | 13 | Dominated | ||
62 | HIV-61: Combination: MED + STI95% | 22 | Dominated | ||
63 | HIV-62: Combination: MED + STIcurrent | 9 | Dominated | ||
64 | HIV-63: Combination: MED + EDS-STI95 + PMTCT + STI95% | 16 | Dominated | ||
65 | HIV-64: Combination: MED + EDS-STI95 + PMTCT + STI95% + VCT | 28 | 290 | ||
66 | HIV-65: Combination: MED + EDS-STI95 + VCT | 18 | Dominated | ||
67 | HIV-66: Combination: MED + EDS-STI95 + VCT + STIcurrent | 20 | Dominated | ||
68 | HIV-67: Combination: MED + EDS-STI95 + VCT + STIenhanced | 21 | Dominated | ||
69 | HIV-68: Combination: MED + EDS-STI95 + VCT + STI-95% | 25 | Dominated | ||
70 | HIV-69: Combination: MED + EDS-STI95 + VCT + STIcurrent + PMTCT | 23 | Dominated | ||
71 | HIV-70: Combination: MED + EDS-STI95 + VCT + STIenhanced + PMTCT | 24 | 220 | ||
72 | HIV-71: Combination: MED + EDS-STI95 + VCT + PMTCT | 22 | Dominated | ||
73 | HIV-72: Combination: MED + EDS-STI95 + STI95% + VCT + HAARTSimpNoDOTS | 66 | Dominated | ||
74 | HIV-73: Combination: MED + EDS-STI95 + STI95% + VCT + HAARTSimpDOTS | 70 | Dominated | ||
75 | HIV-74: Combination: MED + EDS-STI95 + STI95% + VCT + HAARTPlusNoDOTS | 220 | Dominated | ||
76 | HIV-75: Combination: MED + EDS-STI95 + STI95% + VCT + HAARTPlusDOTS | 233 | Dominated | ||
77 | HIV-76: Combination: MED + EDS-STI95 + SBE95 | 7 | Dominated | ||
78 | HIV-77: Combination: MED + EDS-STI95 + STIcurrent + SBE95 | 8 | Dominated | ||
79 | HIV-78: Combination: MED + EDS-STI95 + STIenhanced + SBE95 | 11 | Dominated | ||
80 | HIV-79: Combination: MED + EDS-STI95 + STI95 + SBE95 | 15 | Dominated | ||
81 | HIV-80: Combination: MED + EDS-STI95 + STIcurrent + SBE95 + VCT | 22 | Dominated | ||
82 | HIV-81: Combination: MED + EDS-STI95 + STIenhanced + SBE95 + VCT | 24 | Dominated | ||
83 | HIV-82: Combination: MED + EDS-STI95 + STI95 + SBE95 + VCT | 28 | Dominated | ||
84 | HIV-83: Combination: MED + EDS-STI95 + STIcurrent + SBE95 + PMTCT | 13 | Dominated | ||
85 | HIV-84: Combination: MED + EDS-STI95 + STIenhanced + SBE95 + PMTCT | 15 | Dominated | ||
86 | HIV-85: Combination: MED + EDS-STI95 + STI95 + SBE95 + PMTCT | 19 | Dominated | ||
87 | HIV-86: Combination: MED + EDS-STI95 + PMTCT + VCT + HAARTSimpNoDOTS | 60 | Dominated | ||
88 | HIV-87: Combination: MED + EDS-STI95 + PMTCT + VCT + HAARTSimpNoDOTS + STIcurrent | 61 | Dominated | ||
89 | HIV-88: Combination: MED + EDS-STI95 + PMTCT + VCT + HAARTSimpNoDOTS + STIenhanced | 61 | Dominated | ||
90 | HIV-89: Combination: MED + EDS-STI95 + STIenhanced + SBE95 + VCT + PMTCT | 27 | Dominated | ||
91 | HIV-90: Combination: MED + EDS-STI95 + PMTCT + VCT + HAARTSimpNoDOTS + STI95 | 64 | Dominated | ||
92 | HIV-91: Combination: MED + EDS-STI95 + PMTCT + VCT + HAARTSimpNoDOTS + STIenhanced + SBE95 | 63 | Dominated | ||
93 | Interventions:Codes_and_Descriptions | Average Cost per DALY averted | Incremental Cost per DALY averted | ||
94 | TB-1: SmearPos: Treatment of new smear-positive cases only under DOTS | 6 | 6 | ||
95 | TB-2: SmearPosNeg: As for SmearPos plus treatment of smear-negative cases under DOTS | 10 | Dominated | ||
96 | TB-3: SmearPosMDR: As for SmearPos plus DOTS-plus treatment | 8 | Dominated | ||
97 | TB-4: Combination: As SmearPos plus DOTS treatment of smear-negative cases plus DOTS-plus standardized second-line drug re-treatment | 11 | Dominated | ||
98 | TB-5: SmearPos: Treatment of new smear-positive cases only under DOTS | 7 | 8 | ||
99 | TB-6: SmearPosNeg: As for SmearPos plus treatment of smear-negative cases under DOTS | 11 | Dominated | ||
100 | TB-7: SmearPosMDR: As for SmearPos plus DOTS-plus treatment | 9 | Dominated |